Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from stable antiretroviral therapy to Delstrigo in virologically suppressed adults with HIV-1
ISRCTN42856592Phase 4Completed
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of doravirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Lipid biochemistry change at Week 24 with maintained viral suppression. Started Oct 2022; status: completed.
02
Drugs
doravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN42856592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42856592.